Most Active InvestorsFind investorsBlogPricing
Start for free
Start for free
SC

Stonepine Capital Management

North America, Oregon, United States, Bend

Description

Stonepine Capital Management is a life science focused investment management company.

Investor Profile

Stonepine Capital Management has backed more than 11 startups, with 5 new investments in the last 12 months alone. The firm has led 1 rounds, about 9% of its total and boasts 6 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity rounds (top funding stages).
  • Majority of deals are located in United States, Canada, Ireland.
  • Strong thematic focus on Biotechnology, Health Care, Medical.

Stage Focus

  • Post Ipo Equity (100%)

Country Focus

  • United States (64%)
  • Canada (18%)
  • Ireland (9%)
  • Sweden (9%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Life Science
  • Therapeutics
  • Biopharma
  • Information Technology
  • Personal Health
  • Emergency Medicine
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Stonepine Capital Management frequently co-invest with?

Nantahala Capital Management
Nantahala Capital Management
North America, Connecticut, United States, New Canaan
Co-Investments: 8
Deerfield Management
Deerfield Management
North America, New York, United States, New York
Co-Investments: 1
Amati Global Investors
Amati Global Investors
Europe, Edinburgh, City of, United Kingdom, Edinburgh
Co-Investments: 1
ADAR1 Capital Management
Co-Investments: 2
Sanderling Ventures
Sanderling Ventures
North America, California, United States, San Mateo
Co-Investments: 1
Bering Capital
Bering Capital
North America, California, United States, San Francisco
Co-Investments: 1
Soleus Capital
Soleus Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 2
VC
Velan Capital
North America, Georgia, United States, Alpharetta
Co-Investments: 3
AP
Co-Investments: 2
Aisling Capital
Aisling Capital
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Stonepine Capital Management?

Sol-Gel Technologies

Nes Ziyyona, HaMerkaz, Israel

Sol-Gel Technologies is engaged in the development of a range of specialty pharmaceuticals.

BiotechnologyPharmaceutical
Post Ipo EquityMar 23, 2026
Amount Raised: $33,100,000
Azitra

Branford, Connecticut, United States

Azitra is a clinical-stage medical dermatology company developing microbiome-based novel therapeutics to treat skin conditions and diseases.

Alternative MedicineBiotechnologyConsumer GoodsHealth Care
Post Ipo EquityMar 19, 2026
Amount Raised: $31,000,000
Curis

Cambridge, Massachusetts, United States

Curis is a developed erivedge, a capsule manufactured for the treatment of adults with skin cancer.

BiotechnologyHealth CareMedical
Post Ipo EquityJan 7, 2026
Amount Raised: $80,800,000
IN8Bio

New York, New York, United States

IN8Bio is a biotechnology company focused on delivering a novel off-the-shelf product for the treatment of cancer.

BiotechnologyHealth CareTherapeutics
Post Ipo EquityDec 19, 2025
Amount Raised: $20,100,000
Kazia Therapeutics

Hornsby, New South Wales, Australia

Kazia Therapeutics is an oncology focused biotechnology company.

BiotechnologyClinical TrialsCommercialInnovation ManagementOncologyPharmaceutical
Post Ipo EquityDec 2, 2025
Amount Raised: $32,874,190
Precision BioSciences

Durham, North Carolina, United States

Precision BioSciences is a biotechnology company dedicated to improving life.

BiotechnologyGeneticsHealth CareMedical
Post Ipo EquityNov 10, 2025
Amount Raised: $75,000,000
X4 Pharmaceuticals

Cambridge, Massachusetts, United States

X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.

BiotechnologyClinical TrialsHealth CareOncologyPharmaceuticalTherapeutics
Post Ipo EquityAug 12, 2025
Amount Raised: $85,000,000
Verastem Oncology

Needham, Massachusetts, United States

Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.

BiopharmaBiotechnologyPharmaceutical
Post Ipo EquityApr 25, 2025
Amount Raised: $75,000,000
Edesa Biotech

Markham, Ontario, Canada

Edesa develops treatments for dermatological and anorectal diseases. Edesa merged with Stellar Biotechnologies in 2019.

BiotechnologyLife Science
Post Ipo EquityFeb 13, 2025
Amount Raised: $10,509,103
Grace Therapeutics

Laval, Quebec, Canada

Grace Therapeutics is an emerging biopharmaceutical company.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Post Ipo EquityFeb 10, 2025
Amount Raised: $10,467,142

Find More Investors Like Stonepine Capital Management

Discover similar investors in our database and build your perfect investor list.

post_ipo_equity InvestorsInvestors in BendBrowse All InvestorsTop Investors

Need help with your fundraising strategy?Read our fundraising guides

Decorative background shape
Decorative background shape

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Most Active Investors Find InvestorsNewsletterPricing

Free tools

Pre-Money and Post-Money Valuation Calculator

Investors By Location

San FranciscoNew York CityBostonLos AngelesChicagoLondonParisIndiaSingaporeTel Aviv

Investors By Stage

Angel InvestorsPre-Seed InvestorsSeed InvestorsSeries A InvestorsSeries B InvestorsSeries C InvestorsSeries D Investors